0000950170-23-070174.txt : 20231213
0000950170-23-070174.hdr.sgml : 20231213
20231213215344
ACCESSION NUMBER: 0000950170-23-070174
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231212
FILED AS OF DATE: 20231213
DATE AS OF CHANGE: 20231213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Upton Richard A
CENTRAL INDEX KEY: 0001375726
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40228
FILM NUMBER: 231485449
MAIL ADDRESS:
STREET 1: 12 MIDDLE STREET
CITY: AMHERST
STATE: NH
ZIP: 03031
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Carmell Corp
CENTRAL INDEX KEY: 0001842939
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1177 AVENUE OF THE AMERICAS
STREET 2: 5TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 646-494-3296
MAIL ADDRESS:
STREET 1: 1177 AVENUE OF THE AMERICAS
STREET 2: 5TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: Carmell Therapeutics Corp
DATE OF NAME CHANGE: 20230727
FORMER COMPANY:
FORMER CONFORMED NAME: ALPHA HEALTHCARE ACQUISITION CORP III
DATE OF NAME CHANGE: 20210127
4
1
ownership.xml
4
X0508
4
2023-12-12
0001842939
Carmell Corp
CTCX
0001375726
Upton Richard A
C/O CARMELL CORPORATION
2403 SIDNEY STREET, SUITE 300
PITTSBURGH
PA
15203
true
false
false
false
false
Common Stock
2023-12-12
4
P
false
2000
3.50
A
2000
D
Common Stock
2023-12-13
4
P
false
2400
3.4710
A
4400
D
Common Stock
2021-09-23
4
J
false
0
0
A
44845
D
The price reported in Column 4 is an average price. These shares were purchased in multiple transactions at prices ranging from $3.46 to $3.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2
The shares beneficially owned by the Reporting Person include 44,845 shares of common stock that may be acquired pursuant to the exercise of stock options within 60 days of December 13, 2023.
/s/ Richard Upton
2023-12-13